154 related articles for article (PubMed ID: 30863494)
1. Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.
Alon M; Arafeh R; Lee JS; Madan S; Kalaora S; Nagler A; Abgarian T; Greenberg P; Ruppin E; Samuels Y
Oncotarget; 2019 Feb; 10(13):1344. PubMed ID: 30863494
[TBL] [Abstract][Full Text] [Related]
2. CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.
Alon M; Arafeh R; Lee JS; Madan S; Kalaora S; Nagler A; Abgarian T; Greenberg P; Ruppin E; Samuels Y
Oncotarget; 2018 Jul; 9(58):31264-31277. PubMed ID: 30131853
[TBL] [Abstract][Full Text] [Related]
3. Correction: Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.
Lu HC; Eulo V; Apicelli AJ; Pekmezci M; Tao Y; Luo J; Hirbe AC; Dahiya S
Oncotarget; 2021 Nov; 12(24):2435-2436. PubMed ID: 34853665
[TBL] [Abstract][Full Text] [Related]
4. Correction: Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis.
Marciel MP; Khadka VS; Deng Y; Kilicaslan P; Pham A; Bertino P; Lee K; Chen S; Glibetic N; Hoffmann FW; Matter ML; Hoffmann PR
Oncotarget; 2018 Jul; 9(56):30937. PubMed ID: 30112120
[TBL] [Abstract][Full Text] [Related]
5. Correction: Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells.
Yu X; Ai J; Cai L; Jing Y; Wang D; Dong J; Pascal LE; Zhang J; Luo R; Wang Z
Oncotarget; 2019 Dec; 10(67):7181-7182. PubMed ID: 31903175
[TBL] [Abstract][Full Text] [Related]
6. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
[TBL] [Abstract][Full Text] [Related]
7. Correction: Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC.
Wang Z; Ma B; Li H; Xiao X; Zhou W; Liu F; Zhang B; Zhu M; Yang Q; Zeng Y; Sun Y; Sun S; Wang Y; Zhang Y; Weng H; Chen L; Ye M; An X; Liu J
Oncotarget; 2019 Oct; 10(58):6285. PubMed ID: 31692885
[TBL] [Abstract][Full Text] [Related]
8. Correction: BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells.
Romano E; Rufo N; Korf H; Mathieu C; Garg AD; Agostinis P
Oncotarget; 2018 Dec; 9(97):37076. PubMed ID: 30651937
[TBL] [Abstract][Full Text] [Related]
9. Correction: Proteomic screening identifies the zonula occludens protein ZO-1 as a new partner for ADAM12 in invadopodia-like structures.
Dekky B; Ruff M; Bonnier D; Legagneux V; Théret N
Oncotarget; 2018 Nov; 9(87):35795. PubMed ID: 30515271
[TBL] [Abstract][Full Text] [Related]
10. Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth.
Hanson K; Robinson SD; Al-Yousuf K; Hendry AE; Sexton DW; Sherwood V; Wheeler GN
Oncotarget; 2018 Nov; 9(93):36645. PubMed ID: 30564304
[TBL] [Abstract][Full Text] [Related]
11. Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2018 Nov; 9(88):35870. PubMed ID: 30533201
[TBL] [Abstract][Full Text] [Related]
12. Correction: Tumor suppressor RARRES1 links tubulin deglutamylation to mitochondrial metabolism and cell survival.
Maimouni S; Lee MH; Sung YM; Hall M; Roy A; Ouaari C; Hwang YS; Spivak J; Glasgow E; Swift M; Patel J; Cheema A; Kumar D; Byers S
Oncotarget; 2021 Oct; 12(22):2305-2306. PubMed ID: 34733422
[TBL] [Abstract][Full Text] [Related]
13. Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Kim S; Tiedt R; Loo A; Horn T; Delach S; Kovats S; Haas K; Engstler BS; Cao A; Pinzon-Ortiz M; Mulford I; Acker MG; Chopra R; Brain C; Tomaso ED; Sellers WR; Caponigro G
Oncotarget; 2020 Apr; 11(14):1289. PubMed ID: 32292577
[TBL] [Abstract][Full Text] [Related]
14. Correction: Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.
Hu K; Babapoor-Farrokhran S; Rodrigues M; Deshpande M; Puchner B; Kashiwabuchi F; Hassan SJ; Asnaghi L; Handa JT; Merbs S; Eberhart CG; Semenza GL; Montaner S; Sodhi A
Oncotarget; 2021 Mar; 12(5):519-520. PubMed ID: 33747364
[TBL] [Abstract][Full Text] [Related]
15. Correction: Cutaneous melanoma primary site is linked to nevus density.
Martin-Gorgojo A; Llinares M; Virós A; Requena C; Garcia-Casado Z; Traves V; Kumar R; Nagore E
Oncotarget; 2018 Dec; 9(95):36816. PubMed ID: 30613369
[TBL] [Abstract][Full Text] [Related]
16. Correction: Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1.
Yin SY; Efferth T; Jian FY; Chen YH; Liu CI; Wang AHJ; Chen YR; Hsiao PW; Yang NS
Oncotarget; 2018 Aug; 9(63):32271. PubMed ID: 30181816
[TBL] [Abstract][Full Text] [Related]
17. Status of the NF1 tumor suppressor locus in uveal melanoma.
Foster WJ; Fuller CE; Perry A; Harbour JW
Arch Ophthalmol; 2003 Sep; 121(9):1311-5. PubMed ID: 12963615
[TBL] [Abstract][Full Text] [Related]
18. Correction: Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer.
Terlizzi M; Colarusso C; De Rosa I; De Rosa N; Somma P; Curcio C; Sanduzzi A; Micheli P; Molino A; Saccomanno A; Salvi R; Aquino RP; Pinto A; Sorrentino R
Oncotarget; 2018 Jun; 9(50):29537. PubMed ID: 30034638
[TBL] [Abstract][Full Text] [Related]
19. Correction: Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes.
Hakkim FL; Bakshi HA; Khan S; Nasef MM; Farzand R; Sam S; Rashan L; Al-Baloshi MS; Abdo Hasson SSA; Jabri AA; McCarron PA; Tambuwala MM
Oncotarget; 2020 Jun; 11(23):2259-2261. PubMed ID: 32577169
[TBL] [Abstract][Full Text] [Related]
20. Correction: A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.
Qin T; Barron L; Xia L; Huang H; Villarreal MM; Zwaagstra J; Collins C; Yang J; Zwieb C; Kodali R; Hinck CS; Kim SK; Reddick RL; Shu C; O'Connor-McCourt MD; Hinck AP; Sun LZ
Oncotarget; 2017 Aug; 8(34):57905. PubMed ID: 28915722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
